GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Summit Therapeutics Inc (NAS:SMMT) » Definitions » Current Accrued Expense

Summit Therapeutics (Summit Therapeutics) Current Accrued Expense : $8.78 Mil (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Summit Therapeutics Current Accrued Expense?

Summit Therapeutics's Current Accrued Expense for the quarter that ended in Dec. 2023 was $8.78 Mil.

Summit Therapeutics's quarterly Current Accrued Expense declined from Jun. 2023 ($3.87 Mil) to Sep. 2023 ($3.65 Mil) but then increased from Sep. 2023 ($3.65 Mil) to Dec. 2023 ($8.78 Mil).

Summit Therapeutics's annual Current Accrued Expense increased from Dec. 2021 ($7.20 Mil) to Dec. 2022 ($10.66 Mil) but then declined from Dec. 2022 ($10.66 Mil) to Dec. 2023 ($8.78 Mil).


Summit Therapeutics Current Accrued Expense Historical Data

The historical data trend for Summit Therapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Summit Therapeutics Current Accrued Expense Chart

Summit Therapeutics Annual Data
Trend Jan14 Jan15 Jan16 Jan17 Jan18 Jan19 Dec20 Dec21 Dec22 Dec23
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.20 3.28 7.20 10.66 8.78

Summit Therapeutics Quarterly Data
Jan19 Apr19 Jul19 Oct19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.66 12.30 3.87 3.65 8.78

Summit Therapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.


Summit Therapeutics Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Summit Therapeutics's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Summit Therapeutics (Summit Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
2882 Sand Hill Road, Suite 106, Menlo Park, CA, USA, 94025
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its lead CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Executives
Ankur Dhingra officer: Chief Financial Officer C/O CAREDX, INC., 1 TOWER PLACE, 9TH FLOOR, SOUTH SAN FRANCISCO CA 94080
Maky Zanganeh director 51 ADAM WAY, ATHERTON CA 94027
Manmeet Singh Soni director C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE, SUNNYVALE CA 94085
Robert W Duggan director, 10 percent owner, officer: See Remarks 611 SOUTH FORT HARRISON AVE, SUITE 306, CLEARWATER FL 33756
Yu Xia director 6 SHENNONG ROAD, TORCH DEVELOPMENT ZONE, ZHONGSHAN, GUANGDONG F4 528437
Robert F. Booth director C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Alessandra Cesano director 700 BALTIC CIRCLE, SUITE 716, REDWOOD CITY CA 94065
Urte Gayko director C/O PARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Kenneth A Clark director C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE., SUNNYVALE CA 94085
Jeffrey R Maranian officer: VP, Corporate Controller C/O SUMMIT THERAPEUTICS INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Luhua Wang director ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
David Jonathan Powell officer: Chief Scientific Officer ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Camilla Graham officer: Chief Clinical Affairs Officer ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Ventzislav Stefanov director, officer: See Remarks ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Ujwala Mahatme director ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142

Summit Therapeutics (Summit Therapeutics) Headlines

From GuruFocus

Summit Therapeutics Inc. Investors: Company Investigated by the Portnoy Law Firm

By Stock market mentor Stock market mentor 02-08-2023

Summit Therapeutics Closes Fully-Subscribed $500 Million Rights Offering

By Business Wire Business Wire 03-03-2023